CareSource GLP-1 Coverage & Prior-Authorization Guide (2026)

CareSource does not provide broad coverage of GLP-1s for chronic weight management. Its Medicaid plans follow each state's rules — Ohio uses the state's own Unified Preferred Drug List through Gainwell Technologies rather than a CareSource-specific formulary, and Michigan's HAP CareSource sharply reduced obesity-only GLP-1 coverage effective January 1, 2026. Its Medicare Part D and D-SNP plans are barred by federal statute from covering GLP-1s used solely for weight loss. GLP-1s remain covered for non-weight-loss FDA indications, such as type 2 diabetes (Ozempic, Mounjaro), with prior authorization. We pulled the primary CareSource and HAP CareSource provider notices directly on 2026-07-10 and quote them verbatim below; the KFF state-Medicaid-coverage count was re-verified live on 2026-08-02.

The bottom line

• CareSource does NOT broadly cover GLP-1s for obesity/weight-loss-only indications — coverage is set state by state, and per KFF only 13 states offered GLP-1 obesity coverage under Medicaid as of January 2026, still KFF's most recently published count as of this update (re-checked live August 2026) and a figure KFF itself describes as volatile — down from 16 states in October 2025 after California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage (North Carolina briefly dropped and then restored it), with Massachusetts and Rhode Island reportedly considering dropping coverage next.
• Ohio Medicaid: CareSource does not maintain its own drug formulary for Ohio Medicaid members. Gainwell Technologies is the state's Single PBM and applies the Ohio Department of Medicaid's Unified Preferred Drug List (UPDL) — weight-loss coverage is a state decision, not a CareSource one.
• HAP CareSource (Michigan Medicaid): effective January 1, 2026, coverage of GLP-1 medications prescribed solely to treat obesity — including continuations — was reduced under Michigan Public Act 22 of 2025. Affected drugs: generic liraglutide, Saxenda, Wegovy, and Zepbound. PAs approved before Jan 1, 2026 are honored for their remaining six authorized months.
• Medicare (CareSource Part D / D-SNP): federal law prohibits Medicare from covering medications used specifically for weight loss. A time-limited Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) offers select obesity GLP-1s at a $50/month copay outside Part D.
• Diabetes indication still covered: GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro) are not subject to the weight-loss exclusion and remain covered with prior authorization / step therapy per each state's PDL.

What CareSource actually covers

CareSource does not provide broad coverage of GLP-1s for chronic weight management. Whether a CareSource Medicaid member has any path to obesity-indicated GLP-1 coverage depends almost entirely on which state's Medicaid program the plan operates under, because anti-obesity drug coverage is optional under the federal Medicaid drug-exclusion rule. Per KFF, only 13 states offered GLP-1 obesity coverage under Medicaid as of January 2026 — the most recent figure KFF has published as of this update — so CareSource Medicaid coverage of Wegovy, Zepbound, or Saxenda for obesity depends entirely on the state a member is enrolled in. This number moves: KFF's tracker shows 16 states covering obesity GLP-1s as recently as October 2025, with four (California, New Hampshire, Pennsylvania, South Carolina) eliminating coverage since, and at least two more states reportedly weighing the same move — check KFF's tracker directly for the current count before relying on any specific number here.

In Ohio, CareSource Medicaid does not maintain its own drug formulary. Gainwell Technologies is the Single Pharmacy Benefit Manager for all Ohio Medicaid members and applies the Ohio Department of Medicaid's Unified Preferred Drug List (UPDL) — meaning weight-loss drug coverage in Ohio is set by the state, not by CareSource, and members should consult the Ohio UPDL directly rather than a CareSource-specific document.

For HAP CareSource (Michigan Medicaid), effective January 1, 2026, coverage of GLP-1 medications prescribed solely to treat obesity — including requests for continuation — was reduced under Michigan Public Act 22 of 2025. The affected obesity GLP-1s named in the Michigan provider notice are generic liraglutide (Saxenda), Saxenda, Wegovy, and Zepbound; coverage for non-obesity FDA indications of these same drugs is not changing. Members with prior authorizations approved before January 1, 2026 have those authorizations honored for the remaining six months originally authorized.

CareSource Medicare plans (Part D and D-SNP) cannot cover GLP-1s for weight loss at all — Medicare is prohibited by federal statute from covering medications used specifically for weight loss. A time-limited Medicare GLP-1 Bridge running from July 1, 2026 through December 31, 2027 offers select obesity GLP-1s at a flat $50/month copay outside the standard Part D benefit; separately, CMS announced it would not implement the proposed BALANCE Model in Medicare for 2027.

Throughout all of this, GLP-1s prescribed for type 2 diabetes — Ozempic and Mounjaro — are not subject to the weight-loss exclusion. They remain covered with prior authorization and/or step therapy under each state's Preferred Drug List, independent of the obesity-coverage restrictions described above.

Prior authorization criteria (where coverage exists)

• Michigan (HAP CareSource) obesity GLP-1 PA, effective January 1, 2026: the patient must be classified as morbidly obese.
• Documented failure of all other clinically appropriate weight-loss interventions is required, including a trial and failure of Preferred Drug List (PDL) preferred anti-obesity agents.
• Coverage is considered only as a measure to avert the need for higher-cost bariatric surgery.
• Ohio: obesity GLP-1 PA criteria are set by the Ohio Department of Medicaid Unified PDL / Single PBM (Gainwell), not by CareSource — consult the Ohio UPDL for the current criteria.
• Diabetes-indicated GLP-1s (Ozempic, Mounjaro) are covered under diabetes drug classes with their own PA / step-therapy criteria per each state's PDL, separate from the obesity criteria above.

“Coverage of GLP-1 medications when prescribed solely to treat obesity, including requests for continuation, will be reduced.”

— HAP CareSource Provider Notice: Update of Pharmacy Drug Coverage for Treatment of Obesity (eff. Jan 1, 2026)

“GLP-1 product coverage requested for treatment of obesity will require additional clinical PA requirements such as the following: Patient must be classified as morbidly obese; and Coverage is contingent on documented failure of all other clinically appropriate weight-loss interventions (including a trial and failure of Preferred Drug List [PDL] preferred anti-obesity agents); and Coverage must be considered only as a measure to avert the need for higher-cost bariatric surgery.”

— HAP CareSource Provider Notice: Update of Pharmacy Drug Coverage for Treatment of Obesity

“Gainwell Technologies uses the Ohio Department of Medicaid's Unified Preferred Drug List, or UPDL.”

— CareSource Ohio Medicaid — Preferred Drug List page

How to appeal a denial

For CareSource Ohio Medicaid members, the appeal path runs in two stages. First, file an internal appeal with CareSource within 60 calendar days of the adverse benefit determination notice; CareSource issues a standard decision within 15 calendar days, with an expedited option available for urgent clinical situations. Second, after the plan-level appeal, request a State Hearing with the Ohio Department of Medicaid within 90 calendar days of the notice (MyCare Ohio Waiver members have 120 days). A separate grievance process exists for complaints that are not benefit denials — that process does not follow the same appeal timeline.

Primary-source detail in this article is strongest for Michigan (the HAP CareSource December 2025 provider notice) and the federal Medicaid/Medicare framework (KFF). CareSource operates across many states — Ohio, Indiana, Georgia, Kentucky, West Virginia, Michigan, North Carolina — and multiple lines of business, and coverage varies by state and plan. This article is informational only and is not medical or coverage advice; confirm your specific state's PDL and your own plan's member handbook before relying on any criteria described here. Ohio obesity GLP-1 criteria live in the state Unified PDL (Gainwell) and were not fetched line-by-line for this article. Appeal day-counts reflect standard Ohio Medicaid managed-care timeframes — confirm against your member handbook, since timeframes can differ by state and plan type.

Further reading

• Aetna GLP-1 prior authorization guide
• Best semaglutide providers
• Best tirzepatide providers

References

1. HAP CareSource Provider Notice: Update of Pharmacy Drug Coverage for Treatment of Obesity (eff. Jan 1, 2026)
2. HAP CareSource Provider Notice — GLP-1 PA clinical criteria for obesity coverage
3. CareSource Ohio Medicaid — Preferred Drug List page
4. KFF — Medicaid Coverage of and Spending on GLP-1s (13-state count, as of January 2026)